The data presented in this article are related to the research article entitled "Cyr61/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK/NF-κB pathway" (Pinru Wu, Gang Ma, Xianjin Zhu, Ting Gu, Jie Zhang, Yue Sun, Hui Xu, Rongfen Huo, Beiqing Wang, Baihua Shen, Xiangdong Chen, Ningli Li, 2016) [1]. Cysteine-rich 61 (Cyr61/CCN1), a secreted extracellular matrix protein, is a novel proinflammatory factor. In this dataset skin samples from normal donors and psoriasis vulgaris patients were examined the expression of Cyr61 and IL-8 using immunohistochemistry. IMQ-induced psoriasis-like mice were treated with anti-Cyr61monoclonal antibodies (mAb).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5196240 | PMC |
| http://dx.doi.org/10.1016/j.dib.2016.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cross-sectional study of proteomic differences between moderate and severe psoriasis.
Sci Rep
January 2025
Department of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Although an ongoing understanding of psoriasis vulgaris (PV) pathogenesis, little is known about the proteomic differences between moderate and severe psoriasis. In this cross-sectional study, we evaluated the proteomic differences between moderate and severe psoriasis using data-independent acquisition mass spectrometry (DIA-MS). 173 differentially expressed proteins (DEPs) were significantly differentially expressed between the two groups.
View Article and Find Full Text PDFNew horizons in the treatment of psoriasis: Modulation of gut microbiome.
Heliyon
January 2025
Department of Medical Microbiology, Tehran University of Medical Sciences, Tehran, Iran.
The last decennia have witnessed spectacular advances in our knowledge about the influence of the gut microbiome on the development of a wide swathe of diseases that extend beyond the digestive tract, including skin diseases like psoriasis, atopic dermatitis, acne vulgaris, rosacea, alopecia areata, and hidradenitis suppurativa. The novel concept of the gut-skin axis delves into how skin diseases and the microbiome interact through inflammatory mediators, metabolites, and the intestinal barrier. Elucidating the effects of the gut microbiome on skin health could provide new opportunities for developing innovative treatments for dermatological diseases.
View Article and Find Full Text PDFUnderstanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.
Int J Mol Sci
January 2025
Department of Dermatology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Psoriasis is a chronic inflammatory condition that is polygenic and multisystemic, impacting approximately 2-3% of the global population. The onset of this disease is influenced by an intricate interplay of genetic and environmental factors, predisposing individuals to the psoriasis phenotype. The complex pathogenesis of psoriasis contains certain key aspects found in other autoinflammatory and autoimmune dermatological diseases.
View Article and Find Full Text PDFMisdiagnosis of Leprosy with Severe Reversal Reaction as Psoriatic Arthritis: A Case Report and Literature Review.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
Introduction: Leprosy is a chronic granulomatous disease caused by and . Meanwhile, leprosy reactions are immunologically mediated episodes of acute or subacute inflammation that occur during the chronic course of the disease. Leprosy and leprosy reaction have a wide range of clinical manifestations, including those resembling psoriatic arthritis.
View Article and Find Full Text PDFGenetically mimicked effects of evinacumab on psoriasis: a drug target Mendelian randomization study.
Asia Pac J Clin Nutr
February 2025
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China. Email:
Background And Objectives: Dyslipidemia has been reported to contribute to the psoriasis pathogenesis. Thus, evinacumab, a novel lipid-lowering drug targeting angiopoietin-like 3, may have therapeutic potential to treat and/or manage psoriasis.
Methods And Study Design: Summary statistics were obtained from genome-wide association studies addressing psoriasis (FinnGen Consortium; n=216,752) and serum lipid concentrations (United Kingdom Biobank; n=403,943-440,546).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!